A systematic review of metastatic hepatocellular carcinoma to the spine Journal Article


Authors: Goodwin, C. R.; Yanamadala, V.; Ruiz-Valls, A.; Abu-Bonsrah, N.; Shankar, G.; Sankey, E. W.; Boone, C.; Clarke, M. J.; Bilsky, M.; Laufer, I.; Fisher, C.; Shin, J. H.; Sciubba, D. M.
Article Title: A systematic review of metastatic hepatocellular carcinoma to the spine
Abstract: BACKGROUND: Hepatocellular carcinoma (HCC) frequently metastasizes to the spine. The impact of medical and/or surgical intervention on overall survival has been examined in a limited number of clinical studies, and herein we systematically review these data. METHODS: We performed a literature review using PubMed, Embase, CINAHL, and Web of Science to identify articles that reported survival, clinical outcomes, and/or prognostic factors associated with patients diagnosed with spinal metastases. The methodologic quality of each review was assessed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses tool. RESULTS: There were 26 articles (152 patients) that met the inclusion criteria and were treated with either surgery, radiotherapy, chemotherapy, and/or observation. There were 3 retrospective cohort studies, 17 case reports, 5 case series, and 1 longitudinal observational study. Of the patients with known overall survival after diagnosis of spinal metastasis, survival at 3 months, 6 months, 1 year, 2 years, and 5 years was 95.2%, 83.0%, 28.6%, 2.0%, and 1.4%, respectively. The median survival after diagnosis of the metastasis was 0.7 months in the patients who received no treatment, 7 months in the patients treated with surgical intervention alone, 6 months for patients who received chemotherapy and/or radiation, and 13.5 months in the patients treated with a combination of surgery and medical management. All other clinical or prognostic parameters were of low or insufficient strength. CONCLUSIONS: Patients diagnosed with HCC spinal metastasis have a 10.6-month overall survival. Further analysis of patients in prospective controlled trials will be essential to the development of treatment algorithms for these patients in the future.
Keywords: survival; hepatocellular carcinoma; sorafenib; radiosurgery; surgery; liver cancer; tumor; epidemiology; outcomes; spine metastasis; prognostic-factors; bone metastases; combination; free survival; cord compression; sacroplasty
Journal Title: World Neurosurgery
Volume: 91
ISSN: 1878-8750
Publisher: Elsevier Inc.  
Date Published: 2016-07-01
Start Page: 510
End Page: 517
Language: English
ACCESSION: WOS:000380365000070
DOI: 10.1016/j.wneu.2016.04.026
PROVIDER: wos
PUBMED: 27090971
PMCID: PMC5586495
Notes: Review -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mark H Bilsky
    319 Bilsky
  2. Ilya Laufer
    146 Laufer